『BioTalk Unzipped』のカバーアート

BioTalk Unzipped

BioTalk Unzipped

著者： Gregory Austin
無料で聴く

BioTalk Unzipped, hosted by Gregory Austin and Dr. Chad Briscoe, unzips the stories behind medical progress through candid, intelligent, and often entertaining conversations with leaders across biotechnology, pharmaceuticals, medical technology, clinical research, bioanalysis, and drug development. Each episode explores the science, strategy, setbacks, breakthroughs, and human stories shaping the future of medicine. From first-in-human trials and biomarkers to oncology, rare disease, AI, regulatory strategy, and emerging therapeutic technologies, BioTalk Unzipped makes complex life science topics engaging, accessible, and relevant. The show feels like the conversation you would want to overhear after a great scientific conference: thoughtful, unscripted, curious, and grounded in real-world experience. We bring listeners inside the decisions, discoveries, and personal journeys behind the therapies and technologies that may one day reduce suffering and improve lives.BioTalk Unzipped 生物科学 科学 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

    The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi
    2026/06/11

    Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.

    Sponsored by Leucentra, https://leucentra.com/

    Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.

    In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe speak with Dr. Lakshmi Amaravadi, Head of Oncology Bioanalysis at AstraZeneca, live from AAPS PharmSci 360 in San Antonio.

    Dr. Amaravadi unpacks why biomarker validation is not one-size-fits-all, how context of use should guide scientific decision making, and why fit-for-purpose validation matters in modern oncology drug development.

    The conversation explores:

    00:00 Why oncology bioanalysis is becoming more complex

    02:12 FDA biomarker validation guidance and industry response

    04:27 What “fit for purpose” means in practice

    06:38 PK assay validation vs biomarker assay validation

    07:52 What drives Dr. Amaravadi’s work in translational science

    10:48 Why validation is not a checkbox exercise

    12:19 Advice for young scientists entering bioanalysis

    15:12 Why oncology drug development is uniquely complex

    18:17 ADCs, bispecifics, T-cell engagers, and conditional T-cell engagers

    19:38 Why bioanalysis now requires understanding biology

    20:46 Dr. Amaravadi’s path from molecular biology to bioanalysis

    24:34 Critical reagent management in complex oncology assays

    26:42 Validation, qualification, and context of use

    29:03 Final thoughts from AAPS PharmSci 360

    This episode is especially relevant for scientists, bioanalytical leaders, translational researchers, clinical pharmacologists, oncology development teams, biomarker scientists, and anyone working at the intersection of drug development, assay validation, and precision medicine.

    Dr. Amaravadi discusses how oncology programs now involve ADCs, bispecifics, T-cell engagers, conditional T-cell engagers, complex linkers, multiple measurable species, immunogenicity considerations, and biomarker strategies that require deeper biological understanding. As she explains in the episode, the future of oncology bioanalysis is not simply measuring what is present. It is understanding what the measurement means in the context of the biology and the development decision.

    Follow BioTalk Unzipped for conversations with leaders in biotech, pharma, bioanalysis, clinical development, translational science, regulatory strategy, and the future of medicine.

    Guest

    Dr. Lakshmi Amaravadi

    https://www.linkedin.com/in/lakshmi-amaravadi/

    Hosts

    Gregory Austin

    https://www.linkedin.com/in/gregoryaustin1/

    Dr. Chad Briscoe

    https://www.linkedin.com/in/chadbriscoe/

    Sponsor: Leucentra

    Related Links

    Celerion

    https://www.celerion.com/
    続きを読む 一部表示
    30 分
  • Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

    Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker
    2026/04/25

    Can artificial intelligence help make cancer therapies safer, more targeted, and more effective?

    In this episode of BioTalk Unzipped, Gregory Austin sits down with Dr. Daniel Reker, Assistant Professor at Duke University, for a wide-ranging conversation on active machine learning, nanomedicine, drug delivery, and the future of AI in biomedical research.

    This episode is brought to you by Leucentra.

    Inspired by Science Empowered by IT

    https://leucentra.com/

    Dr. Reker works at the intersection of AI, chemistry, biomedical engineering, pharmacology, and molecular medicine. His lab develops computational and experimental approaches to better understand small molecules, nanoformulations, and drug delivery systems.

    The conversation explores how machine learning can support drug discovery and development, especially in areas where datasets are small and the biology is complex. Dr. Reker explains why nanoformulations may be able to improve targeted drug delivery, reduce toxicity, and potentially revive therapeutic agents that previously failed because of safety or tolerability issues.

    Gregory and Dr. Reker also discuss explainable AI, the risks of black box thinking, AI bias, predictive modeling, FDA considerations, non-animal models, and the responsible use of AI in education and science.

    Topics include:

    • Active machine learning in drug discovery

    • AI and nanomedicine

    • Cancer therapy and targeted drug delivery

    • How nanoformulations may reduce toxicity

    • Small datasets in biomedical AI

    • Explainable AI and scientific trust

    • AI bias and model limitations

    • Regulatory implications for predictive models

    • The role of AI in education and cognitive development

    • The future of integrated data in drug development

    Guest bio:

    Dr. Daniel Reker is an Assistant Professor at Duke University. His research focuses on computational and experimental approaches to molecular medicine, including active machine learning, drug delivery, nanoformulations, small molecules, and translational pharmacology. He was named to Forbes 30 Under 30 Europe in Science and Healthcare.

    Guest contact:

    Dr. Daniel Reker

    Email: daniel.reker@duke.edu

    LinkedIn: https://www.linkedin.com/in/danielreker/

    Duke website: https://rekerlab.pratt.duke.edu/

    Connect with BioTalk Unzipped:

    Gregory Austin

    https://www.linkedin.com/in/gregoryaustin1/

    Dr. Chad Briscoe

    https://www.linkedin.com/in/chadbriscoe/

    BioTalk Unzipped uncovers the stories behind medical progress through conversations with innovators across biotech, pharma, medtech, bioanalysis, clinical research, regulatory science, and drug development.
    続きを読む 一部表示
    51 分
  • Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

    Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains
    2026/03/19
    Why haven’t we cured cancer yet? A Genentech scientist explains the real reason.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Scientist at Genentech Roche, to unpack one of the most important and misunderstood questions in modern medicine.This is a rigorous, scientifically grounded conversation on cancer biology, immunotherapy, and the real constraints shaping oncology drug development today.Dr. Liu brings over a decade of experience across antibody drug conjugates (ADCs), bispecific antibodies, and CAR-T therapies, offering a rare, insider perspective on why a universal cure remains elusive and where meaningful progress is actually being made.Thanks to our Founding Sponsor: LEUCENTRA: Helping teams evaluate, implement, and get real value from IT solutions that support innovation, not slow it down. https://leucentra.com/ What You’ll LearnWhy cancer is not one disease, but more than 200 biologically distinct conditionsWhat “curing cancer” actually means in clinical oncologyHow immunotherapies like checkpoint inhibitors and CAR-T are changing outcomesThe biological limits of eliminating every cancer cellHow tumors evade immune detection and adapt over timeWhy only about 20% of patients respond to immuno-oncology therapiesThe role of biomarkers, molecular profiling, and precision medicineWhy early detection remains one of the biggest unsolved challengesThe economic and regulatory pressures shaping next-generation therapiesKey InsightCancer is not simply something to eliminate.It is a dynamic, adaptive system evolving within the human body. The future of oncology is not just eradication, but control, personalization, and intelligent engagement of the immune system.Notable Quotes“Cancer is a collection of more than 200 diseases, each requiring its own specific approach.”“The cure for some cancers is within reach, but for many others, early detection remains the critical challenge.”“Our immune system is constantly surveilling. The key is learning how to harness it effectively.”Timestamps00:00 – Introduction02:42 – Bob’s passion - AACR04:28 – Why we haven’t cured cancer07:09 – Defining a cancer cure10:26 – Cancer classification and molecular signatures14:16 – Methylation profiling in diagnosis17:22 – Patient resources and navigation21:14 – FDA shifts toward randomized trials for CAR-T24:15 – Cost and access challenges26:33 – Cancer vs cardiovascular disease progress33:39 – The challenge of early detection37:48 – Biomarker limitations39:14 – Immune system dynamics in cancer45:19 – Bioanalytical challenges in modern therapies51:08 – Progress and future outlookAbout the GuestDr. Bob Liu is a Senior Principal Scientist at Genentech Roche specializing in bioanalytical sciences and immunogenicity assessment for advanced oncology therapies, including T-cell bispecifics and CAR-T.Resources & LinksFDA to tighten approval requirements for CAR-T therapieshttps://www.raps.org/news-and-articles/news-articles/2025/12/fda-to-tighten-approval-requirements-for-car-t-celAmerican Association for Cancer Research (AACR)https://www.aacr.org/National Cancer Institute – Molecular diagnostics and biomarkershttps://www.cancer.gov/about-cancer/diagnosis-staging/diagnosisPattern recognition technologies in diagnosticshttps://toby.healthConnectDr. Bob Liuhttps://www.linkedin.com/in/bob-liu-42b8b278/Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/Final ThoughtThe path to curing cancer is not a single breakthrough. It is a long, complex progression of scientific advances, better diagnostics, and deeper biological understanding.The progress is real.But the work is far from finished.
    続きを読む 一部表示
    1 時間
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません